The role of volumetric High-Resolution computed tomography (HRCT) of the chest in the assessment of patients with stable chronic obstructive pulmonary disease (COPD)
NCT ID NCT07809399
First seen Sep 09, 2026 ยท Last updated Sep 09, 2026
Summary
This study evaluates the role of volumetric high-resolution computed tomography (HRCT) of the chest in assessing patients with stable chronic obstructive pulmonary disease (COPD). COPD is a heterogeneous lung condition characterized by chronic pulmonary symptoms, structural airway/alveolar changes, and progressive airflow limitation. While spirometry provides a global assessment of lung function, it cannot localize or fully characterize specific structural abnormalities. Volumetric HRCT allows for detailed, quantitative imaging of lung parenchyma, emphysema extent, air trapping, and airway wall thickness. The primary objective of this cross-sectional observational study is to quantify emphysema, air trapping, and bronchial wall thickness in patients with stable COPD and to evaluate the relationship between these volumetric HRCT findings and clinical measures of disease severity. By identifying objective imaging parameters, this study aims to improve patient evaluation, disease staging, and clinical management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
75 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Aug 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients attending the smoking clinic and chest disease general clinic at Mansoura University Hospital who have stable COPD confirmed by pulmonary function testing.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria:Patients with stable chronic obstructive pulmonary disease (COPD) Diagnosed according to GOLD criteria (post-bronchodilator FEV1/FVC \< 0.70) \- Exclusion Criteria: 1. Patient in exacerbation defined as change in the patient's baseline dyspnea, cough, and/or sputum beyond normal day-to-day variations within 14 days . (Ko, Fanny W., et al 2016) 2. Connective tissue disease . 3. Previously diagnosed Interstitial lung disease 4. Contraindication to PFT According to ATS (Stanojevic S., et al 2021) * Recent Myocardial Infarction Within 1 week * Blood Pressure Instability Severe hypertension or systemic hypotension * Arrhythmias Significant, uncontrolled atrial or ventricular arrhythmias * Decompensated heart failure * Pulmonary Circulation Issues: Uncontrolled pulmonary hypertension, acute cor pulmonale, or clinically unstable pulmonary embolism * History of Syncope Loss of consciousness related to coughing or forced expiration * Cerebral Aneurysm * Recent Brain Surgery: Within 4 weeks * Concussion: Recent concussion with prolonged symptoms * Eye Surgery: Recent eye surgery within 1 week * Pneumothorax: Active or untreated pneumothorax Recent Thoracic Surgery: Within 4 weeks Recent Abdominal Surgery: Within 4 weeks Late-Term Pregnancy 5. Contraindicatins of 6MWT according to ATS : Absolute contraindications * Unstable Angina Experienced during the previous 1 month. * Recent Myocardial Infarction : Within the previous 1 month. Relative contraindications * Resting Tachycardia: Resting heart rate \> 120{ bpm}. * Severe Uncontrolled Hypertension: * Systolic Blood Pressure \> 180{ mmHg} * Diastolic Blood Pressure \> 100{ mmHg} * Symptomatic/Severe Cardiac Conditions: High-degree atrioventricular (AV) block, hypertrophic cardiomyopathy, or symptomatic severe aortic stenosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Airway obstruction are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mansoura University Hospital (Chest Disease Department)
Al Mansurah, Dakahlia Governorate, 35516, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- App alerts COPD patients when their inhalers may be out of date
- Virtual reality may help COPD patients breathe easier during exercise
- Can a new injection help COPD patients cut steroid use?
- Can we untangle the overlap of lung diseases? a new study aims to find out